Lakefront Biotherapeutics has strung together three straight earnings beats and carries a wide stated margin of safety, but revenue is collapsing and margins are deeply compressed, the stock remains in a confirmed downtrend despite a recovering setup, and it has already reached its price target amid a leadership-change flag with a sharply negative stated risk/reward.
Thesis pillars
- Revenue Collapse Margin Compression↑Improving
- Wide Margin Of Safety Valuation→Stable
- Recent Earnings Beat Streak→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026
Lakefront Biotherapeutics (LKFT) Stock Analysis
Recovery setup · Catalyst-Driven edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $32.08, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Earnings estimates trending DOWN.
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus... Read more
Hold if already holding. Not a fresh buy at $32.08, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Earnings estimates trending DOWN. Chart setup: Death cross but MACD improving, RSI 78. Maintain position. Not compelling to add more. Score 5.7/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Lakefront Biotherapeutics
Latest news
- NEWS Lakefront Biotherapeutics Buys Back 97,497 Shares Under Ongoing Repurchase Program - tipranks.com — tipranks.com neutral
- NEWS Morgan Stanley Upgrades Lakefront Biotherapeutics(LKFT.US) to Hold Rating, Raises Target Price to $30 - Moomoo — Moomoo positive
- NEWS Morgan Stanley Upgrades Lakefront Biotherapeutics(LKFT.US) to Hold Rating, Raises Target Price to $30 - moomoo.com — moomoo.com positive
- NEWS Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Posts Earnings Results, Beats Expectations By $1.01 E — MarketBeat positive
- NEWS Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update - The Manila Times — The Manila Times neutral
Generated 2026-10-29T11:14:33Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $32.08, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Earnings estimates trending DOWN. Chart setup: Death cross but MACD improving, RSI 78. Maintain position. Not compelling to add more. Analyst target $25.73 reached (−19.8%), stop $30.70 (−4.5%), A.R:R -1.8:1. Score 5.7/10, moderate confidence.
Analyst target $25.73 reached (−19.8% from $32.08); no take-profit level is published. Analyst target $25.73 reached (−19.8%), stop $30.70 (−4.5%), A.R:R -1.8:1. Stop-loss: $30.70.
Analyst target reached - limited upside remaining; Earnings estimates trending DOWN; Overbought (RSI 78).
Lakefront Biotherapeutics trades at a P/E of 3.0 (forward -26.9). TrendMatrix value score: 5.6/10. Verdict: Hold.
16 analysts cover LKFT with a consensus score of 2.5/5. Average price target: $30.
What does Lakefront Biotherapeutics do?Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily...
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.